- Home
- CRVO vs ATOS Comparison
CRVO vs ATOS Comparison
Compare CRVO & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRVO | ATOS |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9M | 24.1M |
| IPO Year | 2011 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CRVO | ATOS |
|---|---|---|
| Price | $3.10 | $2.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $23.00 | $23.00 |
| AVG Volume (30 Days) | ★ 380.8K | 50.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,006,510.00 | $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $0.53 |
| 52 Week High | $11.25 | $7.56 |
Technical Indicators
Market Signals| Indicator | CRVO | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 44.71 |
| Support Level | $2.82 | $2.05 |
| Resistance Level | $3.86 | $2.60 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 81.82 | 59.09 |
Price Performance
Historical ComparisonAbout CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.